Generic Name: glasdegib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Daurismo is a hedgehog pathway inhibitor approved for treatment of acute myeloid leukemia in newly diagnosed patients who can't use intensive chemotherapy.

General Info

Daurismo is an oral smoothened inhibitor that interferes with the hedgehog signaling pathway, which is thought to enable the survival and growth of cancer stem cells. 

The Phase II BRIGHT 1003 trial showed that first-line Daurismo plus low-dose cytarabine led to longer survival than cytarabine alone (8.3 versus 4.3 months) in patients with acute myeloid leukemia (AML) who were age 75 or older or had conditions such as heart or kidney disease that prevented the use of intensive induction chemotherapy. Daurismo was approved for AML on November 21, 2018.


Dosing Info:

Daurismo is taken as a pill and should be used with low-dose cytarabine chemotherapy.

Side Effects

Common side effects include fatigue, muscle pain, nausea, swelling, shortness of breath, decreased appetite, unusual taste sensation, constipation and rash. Daurismo can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. The Daurismo label includes a warning about heart rhythm abnormalities and the risk of birth defects if used by pregnant women.

For More Info:

Last Reviewed: November 21, 2018